CureVac (CVAC)
(Delayed Data from NSDQ)
$5.47 USD
+0.01 (0.18%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.48 +0.01 (0.18%) 5:42 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CVAC 5.47 +0.01(0.18%)
Will CVAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CVAC
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Kamada (KMDA) Q1 Earnings Match Estimates
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Other News for CVAC
Bird flu emergency response ends as cases decline, CDC says
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
CureVac (CVAC) Downgraded by UBS with Lowered Price Target | CVAC Stock News
CureVac (CVAC) Downgraded by UBS as Acquisition Looms | CVAC Stock News
CureVac downgraded to Neutral from Buy at UBS